TY - JOUR
T1 - Risk of non-melanoma skin cancer in patients with atopic dermatitis treated with oral immunosuppressive drugs
AU - Garritsen, Floor M.
AU - Van Der Schaft, Jorien
AU - van den Reek, Juul M
AU - Politiek, Klaziena
AU - Van Os-Medendorp, Harmieke
AU - van Dijk, Marijke
AU - Hijnen, Dirk J.
AU - De Graaf, Marlies
AU - Bruijnzeel-Koomen, Carla A.
AU - de Jong, Elke M G J
AU - Schuttelaar, Marie-Louise A
AU - De Bruin-Weller, Marjolein S.
N1 - Publisher Copyright:
© 2017 Acta Dermato-Venereologica.
PY - 2017
Y1 - 2017
N2 - There is uncertainty about the risk of developing nonmelanoma skin cancer (NMSC), including basal cell carcinoma and squamous cell carcinoma (SCC), in patients with atopic dermatitis (AD) treated with oral immunosuppressive drugs. A total of 557 patients with AD treated with these drugs in the University Medical Center Utrecht and Groningen, the Netherlands, were analysed. NMSC after oral immunosuppressive treatment was reported in 18 patients (3.2%). The standardized incidence ratio for developing SCC was 13.1 (95% confidence interval (CI) 6.5–19.7). Patients developing NMSC were older at the start of therapy (p < 0.001) and data lock (p < 0.001) compared with patients without NMSC. No significant differences were found in sex, cumulative days of oral immunosuppressive drugs and follow-up between these groups (p = 0.42, p = 0.88, and p = 0.34, respectively). In interpreting these results it is important to include other factors, such as lack of association between treatment duration and tumour development and the long interval between treatment discontinuation and tumour development in some patients.
AB - There is uncertainty about the risk of developing nonmelanoma skin cancer (NMSC), including basal cell carcinoma and squamous cell carcinoma (SCC), in patients with atopic dermatitis (AD) treated with oral immunosuppressive drugs. A total of 557 patients with AD treated with these drugs in the University Medical Center Utrecht and Groningen, the Netherlands, were analysed. NMSC after oral immunosuppressive treatment was reported in 18 patients (3.2%). The standardized incidence ratio for developing SCC was 13.1 (95% confidence interval (CI) 6.5–19.7). Patients developing NMSC were older at the start of therapy (p < 0.001) and data lock (p < 0.001) compared with patients without NMSC. No significant differences were found in sex, cumulative days of oral immunosuppressive drugs and follow-up between these groups (p = 0.42, p = 0.88, and p = 0.34, respectively). In interpreting these results it is important to include other factors, such as lack of association between treatment duration and tumour development and the long interval between treatment discontinuation and tumour development in some patients.
KW - Atopic dermatitis
KW - Non-melanoma skin cancer
KW - Oral immunosuppressive drugs
UR - http://www.scopus.com/inward/record.url?scp=85020092939&partnerID=8YFLogxK
U2 - 10.2340/00015555-2637
DO - 10.2340/00015555-2637
M3 - Article
C2 - 28218345
SN - 0001-5555
VL - 97
SP - 724
EP - 730
JO - Acta Dermato-Venereologica
JF - Acta Dermato-Venereologica
IS - 6
ER -